mercredi 21 septembre 2016

Onco Actu du 21 septembre 2016

1. Biologie

Tardigrade protein helps human DNA withstand radiation [Nature]

2. Etiologie

Large Study Finds No Link Between Vasectomy and Prostate Cancer Risk [ASCO]

3. Prévention

Diet and exercise versus cancer: A science-based view [Science-Based Medicine]

3.1 Tabac

Smoking rates in England fall to lowest on record [BBC News]

3.2 Prévention - Obésité

Warning over Scotland’s childhood obesity figures [Cancer Research UK]

3.6 Prévention - Activité physique

Fitness trackers may not help people keep weight off long-term [STAT]

Report: One in Four Americans over 50 is Inactive [ACS]

Phys Ed: Activity Trackers May Undermine Weight Loss Efforts [NY Times]

Exercise may reduce alcohol-related cancer risk [Reuters]

4.1 Dép., diag. & prono. - Prostate

Prostate Week continues: Yale Cancer Center also flouting evidence with public prostate screening event [HealthNewsReview]

4.2 Dép., diag. & prono. - Génome

Cancer-risk genetic testing reports can vary from lab to lab [Reuters]

4.7 Dép., diag. & prono. - Col de l'utérus

Women dying needlessly due to not attending cervical screening [NHS Choices]

4.9 Dép., diag. & prono. - Sein

Zero deaths’ from breast cancer? NBC viewers misinformed by puff piece on screening test [HealthNewsReview]

5. Traitements

Gene therapy technique may help prevent cancer metastasis [MIT News]

Fighting cancer with sticky nanoparticles [Yale News]

5.10 Traitements - Essais

Clinical Trials: Sharing of Data and Living Up to Our End of the Bargain [NIH Directors's Blog]

Evaluating FDA’s Approach to Cancer Clinical Trials [FDA Voice]

Meeting Patients Where They Are: Liberating Clinical Trials Data Under the Cancer Moonshot [NCI]

US clampdown on clinical-trial reporting is long overdue [Nature]

Obama administration updates rules on publishing results of clinical trials [The Guardian]

VP Biden gives new push on 'Cancer Moonshot' clinical trials [Reuters]

5.12 Immunothérapies

Cancer Immunotherapy At A Crossroads [NPR]

5.2 Pharma

European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer [BMS]

GlaxoSmithKline Appoints Big Pharma's First Woman Chief Executive [Forbes]

GlaxoSmithKline names insider Emma Walmsley as new CEO [Reuters]

5.2.1 Pharma - Partenariats

Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS [KITE]

EORTC Expands Collaborative Agreement with Ignyta for Precision Medicine [EORTC]

Amgen partners with Genenta, San Raffaele on an anti-tumor drug [EndPoints]

Genentech dives into mRNA, betting $310M on BioNTech’s personalized cancer vaccine tech [EndPoints]

5.3 Traitements - FDA, EMA,...

Sarepta Gets An Approval – Unfortunately [In the Pipeline]

Did the FDA set ‘a dangerous precedent’ with its latest drug approval? [STAT]

Approving A Muscular Dystrophy Drug Ignites A Civil War At The FDA [Forbes]

5.3.4 Traitements - AMM (FDA, EMA)

CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma [Lilly]

EMA Recommends Granting a Conditional Marketing Authorisation for Ixazomib [ESMO]

5.4 Traitements - Economie

NICE does not recommend obinutuzumab to treat follicular lymphoma [European Pharmaceutical Review]

5.5 ASCO

ASCO, ASTRO and SSO Update Guideline on Postmastectomy Radiotherapy [ASCO]

5.9 AACR

AACR Cancer Progress Report 2016: Saving Lives Through Research [AACR]

6. Lutte contre les cancers

Changing Cancer Care at Stanford Medicine X [MedGadget]

6.1 Observation

Cancer survival improves in England [Cancer Research UK]

Majority of those with common cancer types 'can expect to live for 10 years' [The Guardian]

6.10.1 Politiques (USA)

In interview, Biden outlines a lifelong role in cancer research, but not in a Clinton White House [STAT]

6.11 Patients

Cancer blogger dies day before her wedding [The Guardian]

6.7.1 Bioinformatique

Microsoft Develops AI to Help Cancer Doctors Find the Right Treatments [Bloomberg]

Microsoft will 'solve' cancer within 10 years by 'reprogramming' diseased cells [The Telegraph]

6.7.2 Applis

An App to Predict Prostate Cancer Relapse? [Cancer Research Catalyst]